Transepithelial photorefractive keratectomy for treatment of low to moderate myopia and astigmatism with aberration free ablation profile

Session Details

Session Title: Refractive
Session Date/Time: Friday 21/02/2020 | 08:15-10:10
Paper Time: 09:30
Venue: Fes 1.

First Author: M.Chahbi MOROCCO
Co Author(s): K. Nayme                 

Abstract Details

Purpose:

'- To evaluate the outcomes of the transepithelial photorefractive keratectomy (PRK) in the treatment of low to moderate myopic astigmatism with a non wavefront-guided-aberration free ablation profile

Setting:

this work was conducted at "Clinique de l'oeil Casablanca"

Methods:

'- In this retrospective study, myopic patients with a preoperative sphere under 6.00 diopters (D). - The treatment was performed with the AMARIS 1050RS laser (SCHWIND eye-tech-solution) The method used an aspheric, aberration-free ablation profile and a standardized epithelial tissue removal of 55 µm in the center and 65 µm at a radius of 4 mm as well as SmartPulse technology. - The treatment target is low order aberrations (spherical and/or cylindrical refraction). Clinical outcome is evaluated after 1, 7 days, after 1, 6 and 12 months.

Results:

A Total number of 3428 transPKR is performed between June 2013 to July 2019.  The preoperative mean Manifest spherical equivalent refraction was −3.72±1.3 diopters (D) There was a significant improvement in UCVA after Trans-PRK (0.1-0 at 1 month and 0.05-0 at 3 months).The predictability showed 90% of eyes within the target correction of less than 0.5D and 99% of eyes less than 1D. The mean refractive cylinder was 2.69 ± 0.75 D preoperatively and 0.50 ± 0.29 D postoperatively, with 91% of the eyes within 0.75 D of the target astigmatism.

Conclusions:

'- Trans-PRK showed safe, effective and predictable results in the correction of low to moderate astigmatism and myopia. Financial disclosure of all authors - We have no financial corporate interest or affiliation with the equipment and / or products mentioned in this presentation.

Financial Disclosure: